Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04010513
Other study ID # 832895
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 3, 2019
Est. completion date August 15, 2020

Study information

Verified date February 2021
Source University of Pennsylvania
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a pilot randomized control trial of 30 women with interstitial cystitis/bladder pain syndrome to determine the feasibility of delivering a hypnosis intervention or usual care on bladder pain (primary outcome) and cerebral blood flow (secondary outcome). Women in the hypnosis group will undergo treatment with three hypnotherapy sessions in addition to a mobile web-based hypnosis application. Neuroimagning (fMRI) will occur after the first follow up visit.


Description:

Available treatments do not provide adequate relief for bladder pain syndrome/interstitial cystitis (BPS/IC), a chronic painful condition that affects 10 million women in the United States. The investigators plan to conduct a pilot randomized control study to determine the feasibility of conducting a combined CBT-hypnosis intervention vs. usual care in women with BPS/IC for a subgroup of women, we will determine the effect of specific hypnotic words on brain function using functional brain imaging. All women will have a pre-existing diagnosis of BPS/IC and their baseline pain prior to therapy and novel (arterial spin labeling) and more traditional (BOLD fMRI) neuroimaging techniques will be collected. Women in the hypnosis group will undergo treatment with three in-person hypnotherapy sessions in addition to a mobile web-based hypnosis application. Women in the usual care group will continue their usual care for BPS/IC. Subjects in both groups will complete a variety of questionnaires on bladder pain, urinary symptoms, sleep, mood, affect, disability, and sexual function before and after treatment. The first follow up visit will occur at the end of treatment (4 weeks after randomization). A select group of patients who are eligible to undergo neuroimaging will be invited to participate in neuroimaging after the first follow up visit. Data will also be collected at a second follow up visit at 2 months after randomization.


Recruitment information / eligibility

Status Completed
Enrollment 31
Est. completion date August 15, 2020
Est. primary completion date August 15, 2020
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Women greater than or equal to 18 years old who are diagnosed with interstitial cystitis or bladder pain syndrome. - Meet AUA criteria for BPS/IC: an unpleasant sensation (pain, pressure, discomfort) perceived to be related to the urinary bladder, associated with lower urinary tract symptoms of more than six weeks, in the absence of infection or other identifiable causes. - A minimum score greater than or equal to 8 on the Interstitial Cystitis Symptom Index and Problem Index will be required for participation. - A negative urinalysis or urine culture within 2 months, - Fluent in English language, - No changes in IC treatment regimen within 4 weeks of beginning assigned intervention. Exclusion Criteria: - Patients who are treatment naive or undergoing 3rd line or higher treatments, - Pregnant or lactating, - Unevaluated hematuria, urinary retention, - A history of cystectomy, urinary diversion or augmentation cystoplasty, - Other sources of bladder pain (stone, uncontrolled recurrent UTI, radiation cystitis, bladder cancer) or who have a primary diagnosis of another chronic pain condition (such as back pain, fibromyalgia).

Study Design


Intervention

Behavioral:
Hypnosis
Women in the hypnosis group will undergo treatment with three in-person hypnosis sessions and will be given access to hypnosis web-app for at home practice.
Other:
Standard of Care
Women in the usual care group will continue their usual care for BPS/IC as dictated by their physicians.

Locations

Country Name City State
United States University of Pennsylvania Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
University of Pennsylvania

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Improvement in bladder pain self-efficacy as measured by the Female Genitourinary Pain Index This index is a well validated and widely used instrument for measuring pain in women with BPS/IC 3 months
See also
  Status Clinical Trial Phase
Completed NCT04313972 - IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone Phase 4
Completed NCT03282318 - A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis Phase 2
Completed NCT03463499 - The Efficacy and Safety of Intravesical Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients N/A
Completed NCT02898220 - Trans-MAPP II Study of Urologic Chronic Pelvin Pain
Terminated NCT02591199 - Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Phase 2
Completed NCT02247557 - Intravesical Instillation of Liposome Encapsulated Botulinum Toxin A (Lipotoxin) in Treatment of Interstitial Cystitis Phase 2
Active, not recruiting NCT01731470 - Intravesical Liposomes for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS) N/A
Completed NCT01197261 - OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS) Phase 2
Completed NCT00971568 - Urinary Biomarkers Characteristic to Interstitial Cystitis N/A
Completed NCT00527917 - A Pilot Clinical Investigation of the Efficacy and Safety of Uracyst® Versus Placebo in Patients With Interstitial Cystitis/Painful Bladder Syndrome. Phase 2
Completed NCT00150488 - URACYST® For the Treatment of GAG Deficient Interstitial Cystitis N/A
Recruiting NCT00094874 - Acupuncture for the Treatment of Interstitial Cystitis (IC) Symptoms Phase 3
Terminated NCT00086684 - Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis Phase 4
Recruiting NCT04845217 - Peppermint Oil for the Treatment of Interstitial Cystitis / Bladder Pain Syndrome Phase 1/Phase 2
Completed NCT04401176 - Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome Phase 2
Recruiting NCT05147779 - Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Peyronie's Disease, ED, and Interstitial Cystitis Phase 1
Suspended NCT04450316 - Low-dose Naltrexone for Bladder Pain Syndrome Phase 2
Completed NCT05179460 - A Study of Pentosan Polysulfate Sodium and the Development of Pigmentary Maculopathy and Pigmentary Retinopathy
Completed NCT02232282 - Acupuncture for Female IC/PBSyndrome and Its Effect on the Urinary Microbiome: A Randomized Controlled Trial N/A
Completed NCT00546858 - Relationship of Interstitial Cystitis to Vulvodynia N/A